The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.

The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has approved a wide range of recombinant DNA (r-DNA)-origin drugs and biologics for manufacture ...

Scientists are developing a microneedle patch that they hope could someday simplify IVF hormone delivery. They've tested it ...

Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.

The new generic drug has been approved for treatment of bovine respiratory disease and associated pyrexia in beef and ...

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.

LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...

Afrezza is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus.